nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—TLK1—salivary gland cancer	0.429	0.608	CbGaD
Bosutinib—MAP2K2—salivary gland cancer	0.277	0.392	CbGaD
Bosutinib—EPHA4—tongue—salivary gland cancer	0.00106	0.0107	CbGeAlD
Bosutinib—ULK3—tongue—salivary gland cancer	0.00104	0.0106	CbGeAlD
Bosutinib—CDK2—neck—salivary gland cancer	0.00103	0.0104	CbGeAlD
Bosutinib—FES—parotid gland—salivary gland cancer	0.00086	0.00874	CbGeAlD
Bosutinib—VRK2—parotid gland—salivary gland cancer	0.00086	0.00874	CbGeAlD
Bosutinib—PHKG1—saliva-secreting gland—salivary gland cancer	0.000859	0.00873	CbGeAlD
Bosutinib—SIK2—connective tissue—salivary gland cancer	0.000849	0.00863	CbGeAlD
Bosutinib—VRK2—saliva-secreting gland—salivary gland cancer	0.000824	0.00837	CbGeAlD
Bosutinib—FES—saliva-secreting gland—salivary gland cancer	0.000824	0.00837	CbGeAlD
Bosutinib—SRMS—connective tissue—salivary gland cancer	0.000773	0.00785	CbGeAlD
Bosutinib—BMX—epithelium—salivary gland cancer	0.000767	0.00779	CbGeAlD
Bosutinib—STK25—parotid gland—salivary gland cancer	0.000757	0.0077	CbGeAlD
Bosutinib—SYK—connective tissue—salivary gland cancer	0.000743	0.00754	CbGeAlD
Bosutinib—PLK2—parotid gland—salivary gland cancer	0.000736	0.00748	CbGeAlD
Bosutinib—CDK2—connective tissue—salivary gland cancer	0.000736	0.00747	CbGeAlD
Bosutinib—STK25—saliva-secreting gland—salivary gland cancer	0.000725	0.00737	CbGeAlD
Bosutinib—PLK2—saliva-secreting gland—salivary gland cancer	0.000705	0.00717	CbGeAlD
Bosutinib—CDK2—epithelium—salivary gland cancer	0.000698	0.0071	CbGeAlD
Bosutinib—MAP2K1—neck—salivary gland cancer	0.000681	0.00692	CbGeAlD
Bosutinib—CSNK1A1—neck—salivary gland cancer	0.000672	0.00683	CbGeAlD
Bosutinib—CLK1—neck—salivary gland cancer	0.000668	0.00678	CbGeAlD
Bosutinib—DMPK—epithelium—salivary gland cancer	0.000663	0.00673	CbGeAlD
Bosutinib—BMP2K—neck—salivary gland cancer	0.000655	0.00666	CbGeAlD
Bosutinib—PLK2—connective tissue—salivary gland cancer	0.000648	0.00659	CbGeAlD
Bosutinib—PRKCQ—lymphoid tissue—salivary gland cancer	0.00063	0.0064	CbGeAlD
Bosutinib—STK4—connective tissue—salivary gland cancer	0.00062	0.0063	CbGeAlD
Bosutinib—FRK—lymphoid tissue—salivary gland cancer	0.000605	0.00615	CbGeAlD
Bosutinib—ERBB4—saliva-secreting gland—salivary gland cancer	0.000596	0.00605	CbGeAlD
Bosutinib—ALK—connective tissue—salivary gland cancer	0.000586	0.00595	CbGeAlD
Bosutinib—TYRO3—connective tissue—salivary gland cancer	0.000586	0.00595	CbGeAlD
Bosutinib—BLK—lymphoid tissue—salivary gland cancer	0.000584	0.00593	CbGeAlD
Bosutinib—PTK2—neck—salivary gland cancer	0.000583	0.00592	CbGeAlD
Bosutinib—TBK1—neck—salivary gland cancer	0.000583	0.00592	CbGeAlD
Bosutinib—LYN—connective tissue—salivary gland cancer	0.000583	0.00592	CbGeAlD
Bosutinib—EPHB2—lymphoid tissue—salivary gland cancer	0.000577	0.00587	CbGeAlD
Bosutinib—BTK—connective tissue—salivary gland cancer	0.000571	0.0058	CbGeAlD
Bosutinib—BCR—parotid gland—salivary gland cancer	0.00057	0.00579	CbGeAlD
Bosutinib—NUAK2—parotid gland—salivary gland cancer	0.00057	0.00579	CbGeAlD
Bosutinib—EPHB3—saliva-secreting gland—salivary gland cancer	0.000567	0.00576	CbGeAlD
Bosutinib—RPS6KB1—neck—salivary gland cancer	0.000561	0.0057	CbGeAlD
Bosutinib—TXK—lymphoid tissue—salivary gland cancer	0.000559	0.00568	CbGeAlD
Bosutinib—CSK—parotid gland—salivary gland cancer	0.000551	0.0056	CbGeAlD
Bosutinib—CSNK1A1—parotid gland—salivary gland cancer	0.000547	0.00556	CbGeAlD
Bosutinib—BCR—saliva-secreting gland—salivary gland cancer	0.000546	0.00555	CbGeAlD
Bosutinib—NUAK2—saliva-secreting gland—salivary gland cancer	0.000546	0.00555	CbGeAlD
Bosutinib—IKBKE—lymph node—salivary gland cancer	0.000544	0.00553	CbGeAlD
Bosutinib—CLK1—parotid gland—salivary gland cancer	0.000544	0.00552	CbGeAlD
Bosutinib—SYK—lymphoid tissue—salivary gland cancer	0.000543	0.00552	CbGeAlD
Bosutinib—ROCK1—connective tissue—salivary gland cancer	0.00054	0.00549	CbGeAlD
Bosutinib—CDK2—lymphoid tissue—salivary gland cancer	0.000538	0.00546	CbGeAlD
Bosutinib—STK26—lymphoid tissue—salivary gland cancer	0.000533	0.00541	CbGeAlD
Bosutinib—CSK—saliva-secreting gland—salivary gland cancer	0.000527	0.00536	CbGeAlD
Bosutinib—BMPR2—connective tissue—salivary gland cancer	0.000525	0.00533	CbGeAlD
Bosutinib—CSNK1A1—saliva-secreting gland—salivary gland cancer	0.000524	0.00533	CbGeAlD
Bosutinib—CLK1—saliva-secreting gland—salivary gland cancer	0.000521	0.00529	CbGeAlD
Bosutinib—ERBB4—epithelium—salivary gland cancer	0.00052	0.00528	CbGeAlD
Bosutinib—ROCK1—epithelium—salivary gland cancer	0.000513	0.00521	CbGeAlD
Bosutinib—CSNK1E—parotid gland—salivary gland cancer	0.000507	0.00515	CbGeAlD
Bosutinib—MAP4K4—connective tissue—salivary gland cancer	0.000505	0.00513	CbGeAlD
Bosutinib—SIK1—parotid gland—salivary gland cancer	0.000499	0.00507	CbGeAlD
Bosutinib—IRAK4—parotid gland—salivary gland cancer	0.000499	0.00507	CbGeAlD
Bosutinib—ULK3—parotid gland—salivary gland cancer	0.000488	0.00496	CbGeAlD
Bosutinib—MAP2K1—connective tissue—salivary gland cancer	0.000488	0.00496	CbGeAlD
Bosutinib—STK25—lymphoid tissue—salivary gland cancer	0.000487	0.00495	CbGeAlD
Bosutinib—CSNK1E—saliva-secreting gland—salivary gland cancer	0.000486	0.00493	CbGeAlD
Bosutinib—CSK—connective tissue—salivary gland cancer	0.000485	0.00492	CbGeAlD
Bosutinib—MAP3K7—parotid gland—salivary gland cancer	0.00048	0.00488	CbGeAlD
Bosutinib—CLK1—connective tissue—salivary gland cancer	0.000478	0.00486	CbGeAlD
Bosutinib—SIK1—saliva-secreting gland—salivary gland cancer	0.000478	0.00486	CbGeAlD
Bosutinib—IRAK4—saliva-secreting gland—salivary gland cancer	0.000478	0.00486	CbGeAlD
Bosutinib—TBK1—parotid gland—salivary gland cancer	0.000475	0.00482	CbGeAlD
Bosutinib—PLK2—lymphoid tissue—salivary gland cancer	0.000474	0.00482	CbGeAlD
Bosutinib—BMP2K—connective tissue—salivary gland cancer	0.00047	0.00477	CbGeAlD
Bosutinib—ERBB3—saliva-secreting gland—salivary gland cancer	0.000469	0.00476	CbGeAlD
Bosutinib—ULK3—saliva-secreting gland—salivary gland cancer	0.000467	0.00475	CbGeAlD
Bosutinib—MAP2K2—saliva-secreting gland—salivary gland cancer	0.000467	0.00475	CbGeAlD
Bosutinib—MAP2K1—epithelium—salivary gland cancer	0.000463	0.00471	CbGeAlD
Bosutinib—MAP3K7—saliva-secreting gland—salivary gland cancer	0.00046	0.00467	CbGeAlD
Bosutinib—RPS6KB1—parotid gland—salivary gland cancer	0.000457	0.00464	CbGeAlD
Bosutinib—PTK2—saliva-secreting gland—salivary gland cancer	0.000455	0.00462	CbGeAlD
Bosutinib—TBK1—saliva-secreting gland—salivary gland cancer	0.000455	0.00462	CbGeAlD
Bosutinib—PTK2B—connective tissue—salivary gland cancer	0.000454	0.00461	CbGeAlD
Bosutinib—STK4—lymphoid tissue—salivary gland cancer	0.000453	0.0046	CbGeAlD
Bosutinib—SIK1—connective tissue—salivary gland cancer	0.000439	0.00446	CbGeAlD
Bosutinib—RPS6KB1—saliva-secreting gland—salivary gland cancer	0.000437	0.00444	CbGeAlD
Bosutinib—SLK—parotid gland—salivary gland cancer	0.000435	0.00442	CbGeAlD
Bosutinib—EPHB4—parotid gland—salivary gland cancer	0.000432	0.00439	CbGeAlD
Bosutinib—ERBB3—connective tissue—salivary gland cancer	0.000431	0.00438	CbGeAlD
Bosutinib—ALK—lymphoid tissue—salivary gland cancer	0.000428	0.00435	CbGeAlD
Bosutinib—TYRO3—lymphoid tissue—salivary gland cancer	0.000428	0.00435	CbGeAlD
Bosutinib—FER—lymphoid tissue—salivary gland cancer	0.000428	0.00435	CbGeAlD
Bosutinib—MAP3K2—connective tissue—salivary gland cancer	0.000426	0.00433	CbGeAlD
Bosutinib—LYN—lymphoid tissue—salivary gland cancer	0.000426	0.00433	CbGeAlD
Bosutinib—EPHA2—parotid gland—salivary gland cancer	0.000424	0.00431	CbGeAlD
Bosutinib—MAP4K1—lymphoid tissue—salivary gland cancer	0.00042	0.00426	CbGeAlD
Bosutinib—PTK2—connective tissue—salivary gland cancer	0.000418	0.00424	CbGeAlD
Bosutinib—BTK—lymphoid tissue—salivary gland cancer	0.000417	0.00424	CbGeAlD
Bosutinib—SLK—saliva-secreting gland—salivary gland cancer	0.000417	0.00423	CbGeAlD
Bosutinib—EPHB4—saliva-secreting gland—salivary gland cancer	0.000414	0.0042	CbGeAlD
Bosutinib—MAP3K3—parotid gland—salivary gland cancer	0.000413	0.0042	CbGeAlD
Bosutinib—MAP4K5—parotid gland—salivary gland cancer	0.000413	0.0042	CbGeAlD
Bosutinib—ERBB3—epithelium—salivary gland cancer	0.000409	0.00415	CbGeAlD
Bosutinib—EPHA2—saliva-secreting gland—salivary gland cancer	0.000406	0.00412	CbGeAlD
Bosutinib—MAP4K2—lymphoid tissue—salivary gland cancer	0.000406	0.00412	CbGeAlD
Bosutinib—RPS6KB1—connective tissue—salivary gland cancer	0.000402	0.00408	CbGeAlD
Bosutinib—AXL—connective tissue—salivary gland cancer	0.000398	0.00404	CbGeAlD
Bosutinib—PTK2—epithelium—salivary gland cancer	0.000397	0.00403	CbGeAlD
Bosutinib—MAP3K3—saliva-secreting gland—salivary gland cancer	0.000396	0.00402	CbGeAlD
Bosutinib—MAP4K5—saliva-secreting gland—salivary gland cancer	0.000396	0.00402	CbGeAlD
Bosutinib—ROCK1—lymphoid tissue—salivary gland cancer	0.000395	0.00401	CbGeAlD
Bosutinib—BMPR2—lymphoid tissue—salivary gland cancer	0.000384	0.0039	CbGeAlD
Bosutinib—YES1—parotid gland—salivary gland cancer	0.000382	0.00388	CbGeAlD
Bosutinib—RPS6KB1—epithelium—salivary gland cancer	0.000381	0.00388	CbGeAlD
Bosutinib—EPHB4—connective tissue—salivary gland cancer	0.00038	0.00386	CbGeAlD
Bosutinib—TAOK3—parotid gland—salivary gland cancer	0.000377	0.00383	CbGeAlD
Bosutinib—MERTK—lymphoid tissue—salivary gland cancer	0.000376	0.00382	CbGeAlD
Bosutinib—FYN—connective tissue—salivary gland cancer	0.000372	0.00378	CbGeAlD
Bosutinib—MAP4K4—lymphoid tissue—salivary gland cancer	0.000369	0.00375	CbGeAlD
Bosutinib—BCR—lymphoid tissue—salivary gland cancer	0.000367	0.00373	CbGeAlD
Bosutinib—YES1—saliva-secreting gland—salivary gland cancer	0.000366	0.00372	CbGeAlD
Bosutinib—TAOK3—saliva-secreting gland—salivary gland cancer	0.000361	0.00367	CbGeAlD
Bosutinib—EPHB4—epithelium—salivary gland cancer	0.000361	0.00367	CbGeAlD
Bosutinib—TLK1—lymph node—salivary gland cancer	0.00036	0.00366	CbGeAlD
Bosutinib—PDGFRB—neck—salivary gland cancer	0.000359	0.00365	CbGeAlD
Bosutinib—MAP2K1—lymphoid tissue—salivary gland cancer	0.000357	0.00362	CbGeAlD
Bosutinib—PRKCQ—lymph node—salivary gland cancer	0.000355	0.00361	CbGeAlD
Bosutinib—CSK—lymphoid tissue—salivary gland cancer	0.000354	0.0036	CbGeAlD
Bosutinib—EPHA2—epithelium—salivary gland cancer	0.000354	0.0036	CbGeAlD
Bosutinib—CSNK1A1—lymphoid tissue—salivary gland cancer	0.000352	0.00358	CbGeAlD
Bosutinib—HCK—lymphoid tissue—salivary gland cancer	0.00035	0.00355	CbGeAlD
Bosutinib—CLK1—lymphoid tissue—salivary gland cancer	0.00035	0.00355	CbGeAlD
Bosutinib—MAP2K5—parotid gland—salivary gland cancer	0.000338	0.00343	CbGeAlD
Bosutinib—YES1—connective tissue—salivary gland cancer	0.000336	0.00341	CbGeAlD
Bosutinib—DSTYK—lymph node—salivary gland cancer	0.000333	0.00339	CbGeAlD
Bosutinib—BMX—lymph node—salivary gland cancer	0.000333	0.00339	CbGeAlD
Bosutinib—CLK3—lymph node—salivary gland cancer	0.000333	0.00339	CbGeAlD
Bosutinib—PTK2B—lymphoid tissue—salivary gland cancer	0.000332	0.00337	CbGeAlD
Bosutinib—TAOK3—connective tissue—salivary gland cancer	0.000332	0.00337	CbGeAlD
Bosutinib—BLK—lymph node—salivary gland cancer	0.00033	0.00335	CbGeAlD
Bosutinib—PHKG1—lymph node—salivary gland cancer	0.000326	0.00331	CbGeAlD
Bosutinib—CASK—lymph node—salivary gland cancer	0.000326	0.00331	CbGeAlD
Bosutinib—MAP2K5—saliva-secreting gland—salivary gland cancer	0.000324	0.00329	CbGeAlD
Bosutinib—SRC—connective tissue—salivary gland cancer	0.000323	0.00328	CbGeAlD
Bosutinib—EIF2AK1—lymph node—salivary gland cancer	0.000322	0.00327	CbGeAlD
Bosutinib—SIK1—lymphoid tissue—salivary gland cancer	0.000321	0.00326	CbGeAlD
Bosutinib—IRAK4—lymphoid tissue—salivary gland cancer	0.000321	0.00326	CbGeAlD
Bosutinib—TXK—lymph node—salivary gland cancer	0.000316	0.00321	CbGeAlD
Bosutinib—ERBB3—lymphoid tissue—salivary gland cancer	0.000315	0.0032	CbGeAlD
Bosutinib—MAP2K2—lymphoid tissue—salivary gland cancer	0.000314	0.00319	CbGeAlD
Bosutinib—FES—lymph node—salivary gland cancer	0.000312	0.00317	CbGeAlD
Bosutinib—VRK2—lymph node—salivary gland cancer	0.000312	0.00317	CbGeAlD
Bosutinib—MAP3K2—lymphoid tissue—salivary gland cancer	0.000312	0.00317	CbGeAlD
Bosutinib—SRC—epithelium—salivary gland cancer	0.000307	0.00312	CbGeAlD
Bosutinib—SYK—lymph node—salivary gland cancer	0.000306	0.00311	CbGeAlD
Bosutinib—TNIK—lymph node—salivary gland cancer	0.000306	0.00311	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—salivary gland cancer	0.000305	0.0031	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—salivary gland cancer	0.000305	0.0031	CbGeAlD
Bosutinib—CDK2—lymph node—salivary gland cancer	0.000303	0.00308	CbGeAlD
Bosutinib—STK26—lymph node—salivary gland cancer	0.000301	0.00306	CbGeAlD
Bosutinib—RPS6KB1—lymphoid tissue—salivary gland cancer	0.000294	0.00299	CbGeAlD
Bosutinib—PDGFRB—parotid gland—salivary gland cancer	0.000292	0.00297	CbGeAlD
Bosutinib—FGR—lymphoid tissue—salivary gland cancer	0.000292	0.00297	CbGeAlD
Bosutinib—AXL—lymphoid tissue—salivary gland cancer	0.000291	0.00296	CbGeAlD
Bosutinib—CHEK2—lymph node—salivary gland cancer	0.00029	0.00295	CbGeAlD
Bosutinib—CSF1R—connective tissue—salivary gland cancer	0.00029	0.00295	CbGeAlD
Bosutinib—DMPK—lymph node—salivary gland cancer	0.000288	0.00293	CbGeAlD
Bosutinib—WEE1—lymph node—salivary gland cancer	0.000288	0.00293	CbGeAlD
Bosutinib—PDGFRB—saliva-secreting gland—salivary gland cancer	0.00028	0.00285	CbGeAlD
Bosutinib—STK25—lymph node—salivary gland cancer	0.000275	0.00279	CbGeAlD
Bosutinib—EPHA3—lymph node—salivary gland cancer	0.000273	0.00277	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—salivary gland cancer	0.000273	0.00277	CbGeAlD
Bosutinib—FYN—lymphoid tissue—salivary gland cancer	0.000272	0.00277	CbGeAlD
Bosutinib—PLK2—lymph node—salivary gland cancer	0.000267	0.00272	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—salivary gland cancer	0.000266	0.0027	CbGeAlD
Bosutinib—SIK3—lymph node—salivary gland cancer	0.000266	0.0027	CbGeAlD
Bosutinib—ABL1—parotid gland—salivary gland cancer	0.000261	0.00265	CbGeAlD
Bosutinib—PDGFRB—connective tissue—salivary gland cancer	0.000257	0.00261	CbGeAlD
Bosutinib—STK4—lymph node—salivary gland cancer	0.000256	0.0026	CbGeAlD
Bosutinib—CAMK1D—lymph node—salivary gland cancer	0.000253	0.00257	CbGeAlD
Bosutinib—STK24—lymph node—salivary gland cancer	0.00025	0.00254	CbGeAlD
Bosutinib—ABL1—saliva-secreting gland—salivary gland cancer	0.00025	0.00254	CbGeAlD
Bosutinib—YES1—lymphoid tissue—salivary gland cancer	0.000246	0.0025	CbGeAlD
Bosutinib—PDGFRB—epithelium—salivary gland cancer	0.000244	0.00248	CbGeAlD
Bosutinib—STK10—lymphoid tissue—salivary gland cancer	0.000243	0.00247	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—salivary gland cancer	0.000243	0.00246	CbGeAlD
Bosutinib—FER—lymph node—salivary gland cancer	0.000242	0.00246	CbGeAlD
Bosutinib—ALK—lymph node—salivary gland cancer	0.000242	0.00246	CbGeAlD
Bosutinib—MAP4K1—lymph node—salivary gland cancer	0.000237	0.00241	CbGeAlD
Bosutinib—SRC—lymphoid tissue—salivary gland cancer	0.000236	0.0024	CbGeAlD
Bosutinib—BTK—lymph node—salivary gland cancer	0.000236	0.00239	CbGeAlD
Bosutinib—TNK2—lymph node—salivary gland cancer	0.000232	0.00236	CbGeAlD
Bosutinib—ABL1—connective tissue—salivary gland cancer	0.000229	0.00233	CbGeAlD
Bosutinib—MAP4K2—lymph node—salivary gland cancer	0.000229	0.00233	CbGeAlD
Bosutinib—STK3—lymph node—salivary gland cancer	0.000226	0.00229	CbGeAlD
Bosutinib—BMPR2—lymph node—salivary gland cancer	0.000217	0.0022	CbGeAlD
Bosutinib—STK36—lymph node—salivary gland cancer	0.000215	0.00218	CbGeAlD
Bosutinib—EPHB3—lymph node—salivary gland cancer	0.000215	0.00218	CbGeAlD
Bosutinib—MERTK—lymph node—salivary gland cancer	0.000212	0.00216	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—salivary gland cancer	0.000212	0.00216	CbGeAlD
Bosutinib—MAP4K4—lymph node—salivary gland cancer	0.000208	0.00212	CbGeAlD
Bosutinib—NUAK2—lymph node—salivary gland cancer	0.000207	0.0021	CbGeAlD
Bosutinib—BCR—lymph node—salivary gland cancer	0.000207	0.0021	CbGeAlD
Bosutinib—MAP3K12—lymph node—salivary gland cancer	0.000205	0.00209	CbGeAlD
Bosutinib—MAP2K1—lymph node—salivary gland cancer	0.000201	0.00205	CbGeAlD
Bosutinib—STK35—lymph node—salivary gland cancer	0.000201	0.00205	CbGeAlD
Bosutinib—CSK—lymph node—salivary gland cancer	0.0002	0.00203	CbGeAlD
Bosutinib—CSNK1A1—lymph node—salivary gland cancer	0.000199	0.00202	CbGeAlD
Bosutinib—HCK—lymph node—salivary gland cancer	0.000197	0.00201	CbGeAlD
Bosutinib—CLK1—lymph node—salivary gland cancer	0.000197	0.00201	CbGeAlD
Bosutinib—ABL2—lymph node—salivary gland cancer	0.000196	0.00199	CbGeAlD
Bosutinib—CAMK2G—lymph node—salivary gland cancer	0.000194	0.00197	CbGeAlD
Bosutinib—BMP2K—lymph node—salivary gland cancer	0.000194	0.00197	CbGeAlD
Bosutinib—LRRK2—lymph node—salivary gland cancer	0.000192	0.00195	CbGeAlD
Bosutinib—EGFR—lymph node—salivary gland cancer	0.000191	0.00195	CbGeAlD
Bosutinib—PDGFRB—lymphoid tissue—salivary gland cancer	0.000188	0.00191	CbGeAlD
Bosutinib—PTK2B—lymph node—salivary gland cancer	0.000187	0.0019	CbGeAlD
Bosutinib—CSNK1E—lymph node—salivary gland cancer	0.000184	0.00187	CbGeAlD
Bosutinib—SIK1—lymph node—salivary gland cancer	0.000181	0.00184	CbGeAlD
Bosutinib—IRAK4—lymph node—salivary gland cancer	0.000181	0.00184	CbGeAlD
Bosutinib—EPHA4—lymph node—salivary gland cancer	0.000179	0.00182	CbGeAlD
Bosutinib—ERBB3—lymph node—salivary gland cancer	0.000178	0.00181	CbGeAlD
Bosutinib—MAP2K2—lymph node—salivary gland cancer	0.000177	0.0018	CbGeAlD
Bosutinib—ULK3—lymph node—salivary gland cancer	0.000177	0.0018	CbGeAlD
Bosutinib—MAP3K2—lymph node—salivary gland cancer	0.000176	0.00179	CbGeAlD
Bosutinib—MAP3K7—lymph node—salivary gland cancer	0.000174	0.00177	CbGeAlD
Bosutinib—TBK1—lymph node—salivary gland cancer	0.000172	0.00175	CbGeAlD
Bosutinib—PTK2—lymph node—salivary gland cancer	0.000172	0.00175	CbGeAlD
Bosutinib—IRAK1—lymph node—salivary gland cancer	0.000169	0.00172	CbGeAlD
Bosutinib—ABL1—lymphoid tissue—salivary gland cancer	0.000168	0.0017	CbGeAlD
Bosutinib—RPS6KB1—lymph node—salivary gland cancer	0.000166	0.00168	CbGeAlD
Bosutinib—FGR—lymph node—salivary gland cancer	0.000165	0.00167	CbGeAlD
Bosutinib—LCK—lymph node—salivary gland cancer	0.000165	0.00167	CbGeAlD
Bosutinib—AXL—lymph node—salivary gland cancer	0.000164	0.00167	CbGeAlD
Bosutinib—SLK—lymph node—salivary gland cancer	0.000158	0.0016	CbGeAlD
Bosutinib—EPHB4—lymph node—salivary gland cancer	0.000157	0.00159	CbGeAlD
Bosutinib—EPHA2—lymph node—salivary gland cancer	0.000154	0.00156	CbGeAlD
Bosutinib—FYN—lymph node—salivary gland cancer	0.000154	0.00156	CbGeAlD
Bosutinib—MAP3K3—lymph node—salivary gland cancer	0.00015	0.00152	CbGeAlD
Bosutinib—MAP4K5—lymph node—salivary gland cancer	0.00015	0.00152	CbGeAlD
Bosutinib—YES1—lymph node—salivary gland cancer	0.000139	0.00141	CbGeAlD
Bosutinib—STK10—lymph node—salivary gland cancer	0.000137	0.0014	CbGeAlD
Bosutinib—TAOK3—lymph node—salivary gland cancer	0.000137	0.00139	CbGeAlD
Bosutinib—SRC—lymph node—salivary gland cancer	0.000133	0.00135	CbGeAlD
Bosutinib—MAP2K5—lymph node—salivary gland cancer	0.000123	0.00125	CbGeAlD
Bosutinib—CSF1R—lymph node—salivary gland cancer	0.00012	0.00122	CbGeAlD
Bosutinib—PDGFRB—lymph node—salivary gland cancer	0.000106	0.00108	CbGeAlD
Bosutinib—ABL1—lymph node—salivary gland cancer	9.46e-05	0.000961	CbGeAlD
Bosutinib—ABCB1—epithelium—salivary gland cancer	6.77e-05	0.000688	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—salivary gland cancer	5.22e-05	0.00053	CbGeAlD
Bosutinib—ABCB1—lymph node—salivary gland cancer	2.94e-05	0.000299	CbGeAlD
Bosutinib—ERBB4—Signaling Pathways—EP300—salivary gland cancer	1.54e-06	7.88e-06	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—HRAS—salivary gland cancer	1.54e-06	7.87e-06	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—salivary gland cancer	1.54e-06	7.87e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	1.54e-06	7.86e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PTEN—salivary gland cancer	1.53e-06	7.85e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CCND1—salivary gland cancer	1.53e-06	7.83e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CCND1—salivary gland cancer	1.53e-06	7.83e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CREBBP—salivary gland cancer	1.53e-06	7.82e-06	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HRAS—salivary gland cancer	1.53e-06	7.82e-06	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—salivary gland cancer	1.53e-06	7.8e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EP300—salivary gland cancer	1.52e-06	7.77e-06	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—HRAS—salivary gland cancer	1.51e-06	7.73e-06	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—HRAS—salivary gland cancer	1.51e-06	7.73e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PTEN—salivary gland cancer	1.51e-06	7.72e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOTCH1—salivary gland cancer	1.51e-06	7.71e-06	CbGpPWpGaD
Bosutinib—ERBB4—Disease—HRAS—salivary gland cancer	1.51e-06	7.71e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAP2K2—salivary gland cancer	1.5e-06	7.65e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NOTCH1—salivary gland cancer	1.49e-06	7.63e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—PIK3CA—salivary gland cancer	1.49e-06	7.6e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	1.48e-06	7.57e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PTEN—salivary gland cancer	1.48e-06	7.56e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PTEN—salivary gland cancer	1.48e-06	7.56e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CCND1—salivary gland cancer	1.48e-06	7.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PTEN—salivary gland cancer	1.47e-06	7.54e-06	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—HRAS—salivary gland cancer	1.47e-06	7.53e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOTCH1—salivary gland cancer	1.47e-06	7.53e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CREBBP—salivary gland cancer	1.47e-06	7.5e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EP300—salivary gland cancer	1.46e-06	7.49e-06	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—HRAS—salivary gland cancer	1.46e-06	7.46e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CDH1—salivary gland cancer	1.46e-06	7.44e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—PTEN—salivary gland cancer	1.44e-06	7.38e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAP2K2—salivary gland cancer	1.44e-06	7.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOTCH1—salivary gland cancer	1.44e-06	7.37e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EP300—salivary gland cancer	1.44e-06	7.37e-06	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HRAS—salivary gland cancer	1.44e-06	7.36e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PTEN—salivary gland cancer	1.44e-06	7.34e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—PIK3CA—salivary gland cancer	1.44e-06	7.34e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—PIK3CA—salivary gland cancer	1.43e-06	7.33e-06	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	1.43e-06	7.32e-06	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—PIK3CA—salivary gland cancer	1.43e-06	7.3e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PTEN—salivary gland cancer	1.43e-06	7.29e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PTEN—salivary gland cancer	1.42e-06	7.26e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOTCH1—salivary gland cancer	1.42e-06	7.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PTEN—salivary gland cancer	1.41e-06	7.23e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOTCH1—salivary gland cancer	1.41e-06	7.21e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EP300—salivary gland cancer	1.41e-06	7.21e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EP300—salivary gland cancer	1.41e-06	7.21e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—PIK3CA—salivary gland cancer	1.41e-06	7.2e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EP300—salivary gland cancer	1.41e-06	7.19e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PTEN—salivary gland cancer	1.39e-06	7.13e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—PIK3CA—salivary gland cancer	1.38e-06	7.08e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—EP300—salivary gland cancer	1.38e-06	7.04e-06	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—PIK3CA—salivary gland cancer	1.38e-06	7.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HRAS—salivary gland cancer	1.38e-06	7.03e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EP300—salivary gland cancer	1.37e-06	7e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CREBBP—salivary gland cancer	1.37e-06	6.99e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—PIK3CA—salivary gland cancer	1.37e-06	6.98e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—salivary gland cancer	1.36e-06	6.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PTEN—salivary gland cancer	1.36e-06	6.96e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EP300—salivary gland cancer	1.36e-06	6.95e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—EP300—salivary gland cancer	1.35e-06	6.93e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CREBBP—salivary gland cancer	1.35e-06	6.92e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EP300—salivary gland cancer	1.35e-06	6.89e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AQP1—salivary gland cancer	1.34e-06	6.87e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CREBBP—salivary gland cancer	1.33e-06	6.82e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EP300—salivary gland cancer	1.33e-06	6.8e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—HRAS—salivary gland cancer	1.33e-06	6.79e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—HRAS—salivary gland cancer	1.33e-06	6.79e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HRAS—salivary gland cancer	1.33e-06	6.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HRAS—salivary gland cancer	1.32e-06	6.75e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—PIK3CA—salivary gland cancer	1.32e-06	6.75e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCND1—salivary gland cancer	1.31e-06	6.72e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PTEN—salivary gland cancer	1.31e-06	6.71e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CREBBP—salivary gland cancer	1.31e-06	6.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTEN—salivary gland cancer	1.3e-06	6.67e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—HRAS—salivary gland cancer	1.3e-06	6.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EP300—salivary gland cancer	1.3e-06	6.64e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCND1—salivary gland cancer	1.3e-06	6.63e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—PIK3CA—salivary gland cancer	1.29e-06	6.62e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CREBBP—salivary gland cancer	1.29e-06	6.58e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HRAS—salivary gland cancer	1.28e-06	6.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CREBBP—salivary gland cancer	1.28e-06	6.54e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—salivary gland cancer	1.28e-06	6.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAP2K2—salivary gland cancer	1.28e-06	6.53e-06	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HRAS—salivary gland cancer	1.27e-06	6.51e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PTEN—salivary gland cancer	1.27e-06	6.49e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—PIK3CA—salivary gland cancer	1.27e-06	6.49e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—HRAS—salivary gland cancer	1.26e-06	6.46e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PTEN—salivary gland cancer	1.25e-06	6.4e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EP300—salivary gland cancer	1.25e-06	6.4e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EP300—salivary gland cancer	1.24e-06	6.36e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCND1—salivary gland cancer	1.23e-06	6.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PTEN—salivary gland cancer	1.23e-06	6.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOTCH1—salivary gland cancer	1.23e-06	6.27e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HRAS—salivary gland cancer	1.22e-06	6.24e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—PIK3CA—salivary gland cancer	1.22e-06	6.23e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—PIK3CA—salivary gland cancer	1.22e-06	6.23e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EP300—salivary gland cancer	1.21e-06	6.19e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—salivary gland cancer	1.2e-06	6.13e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EP300—salivary gland cancer	1.19e-06	6.1e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PTEN—salivary gland cancer	1.19e-06	6.07e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PTEN—salivary gland cancer	1.18e-06	6.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOTCH1—salivary gland cancer	1.18e-06	6.04e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—salivary gland cancer	1.17e-06	6e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—EP300—salivary gland cancer	1.17e-06	5.99e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—PIK3CA—salivary gland cancer	1.17e-06	5.96e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCND1—salivary gland cancer	1.16e-06	5.92e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—PIK3CA—salivary gland cancer	1.14e-06	5.83e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTEN—salivary gland cancer	1.13e-06	5.79e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EP300—salivary gland cancer	1.13e-06	5.79e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—salivary gland cancer	1.13e-06	5.77e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EP300—salivary gland cancer	1.13e-06	5.77e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—salivary gland cancer	1.13e-06	5.76e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—PIK3CA—salivary gland cancer	1.12e-06	5.75e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PTEN—salivary gland cancer	1.12e-06	5.71e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CREBBP—salivary gland cancer	1.11e-06	5.68e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—salivary gland cancer	1.1e-06	5.64e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTEN—salivary gland cancer	1.09e-06	5.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—PIK3CA—salivary gland cancer	1.09e-06	5.58e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—salivary gland cancer	1.09e-06	5.56e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PIK3CA—salivary gland cancer	1.08e-06	5.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—EP300—salivary gland cancer	1.08e-06	5.53e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—salivary gland cancer	1.08e-06	5.52e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CREBBP—salivary gland cancer	1.07e-06	5.48e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NUP62—salivary gland cancer	1.07e-06	5.45e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EP300—salivary gland cancer	1.07e-06	5.45e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PIK3CA—salivary gland cancer	1.07e-06	5.45e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—VCAN—salivary gland cancer	1.06e-06	5.41e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—salivary gland cancer	1.06e-06	5.4e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—salivary gland cancer	1.05e-06	5.36e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PTEN—salivary gland cancer	1.05e-06	5.35e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOTCH1—salivary gland cancer	1.05e-06	5.35e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PIK3CA—salivary gland cancer	1.04e-06	5.33e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PIK3CA—salivary gland cancer	1.04e-06	5.33e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EP300—salivary gland cancer	1.04e-06	5.33e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—salivary gland cancer	1.04e-06	5.32e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PIK3CA—salivary gland cancer	1.04e-06	5.32e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—PIK3CA—salivary gland cancer	1.02e-06	5.21e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PIK3CA—salivary gland cancer	1.01e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—salivary gland cancer	1.01e-06	5.17e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—salivary gland cancer	1.01e-06	5.16e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—salivary gland cancer	1.01e-06	5.16e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—salivary gland cancer	1.01e-06	5.16e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PIK3CA—salivary gland cancer	1.01e-06	5.14e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PIK3CA—salivary gland cancer	1e-06	5.12e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—salivary gland cancer	1e-06	5.12e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EP300—salivary gland cancer	9.98e-07	5.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—salivary gland cancer	9.97e-07	5.1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—salivary gland cancer	9.87e-07	5.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—salivary gland cancer	9.86e-07	5.04e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—salivary gland cancer	9.84e-07	5.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—salivary gland cancer	9.76e-07	4.99e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—salivary gland cancer	9.73e-07	4.97e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—salivary gland cancer	9.67e-07	4.94e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—salivary gland cancer	9.66e-07	4.94e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—salivary gland cancer	9.65e-07	4.94e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—salivary gland cancer	9.65e-07	4.94e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—salivary gland cancer	9.62e-07	4.92e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—salivary gland cancer	9.6e-07	4.91e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—salivary gland cancer	9.53e-07	4.87e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—salivary gland cancer	9.52e-07	4.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CREBBP—salivary gland cancer	9.48e-07	4.85e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—salivary gland cancer	9.48e-07	4.85e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—salivary gland cancer	9.46e-07	4.84e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—salivary gland cancer	9.42e-07	4.82e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—salivary gland cancer	9.37e-07	4.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—salivary gland cancer	9.33e-07	4.77e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EP300—salivary gland cancer	9.31e-07	4.76e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—salivary gland cancer	9.3e-07	4.76e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—salivary gland cancer	9.27e-07	4.74e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—salivary gland cancer	9.25e-07	4.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—salivary gland cancer	9.22e-07	4.72e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EP300—salivary gland cancer	9.22e-07	4.71e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—salivary gland cancer	9.2e-07	4.71e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—salivary gland cancer	9.18e-07	4.7e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—salivary gland cancer	9.13e-07	4.67e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—salivary gland cancer	9.1e-07	4.65e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EP300—salivary gland cancer	9.09e-07	4.65e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—salivary gland cancer	8.95e-07	4.58e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—salivary gland cancer	8.9e-07	4.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—salivary gland cancer	8.88e-07	4.54e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—salivary gland cancer	8.83e-07	4.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—salivary gland cancer	8.77e-07	4.48e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—salivary gland cancer	8.76e-07	4.48e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—salivary gland cancer	8.71e-07	4.46e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—salivary gland cancer	8.66e-07	4.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—salivary gland cancer	8.66e-07	4.43e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—salivary gland cancer	8.56e-07	4.38e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—salivary gland cancer	8.54e-07	4.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—salivary gland cancer	8.51e-07	4.35e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—salivary gland cancer	8.37e-07	4.28e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—salivary gland cancer	8.34e-07	4.27e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—salivary gland cancer	8.28e-07	4.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—salivary gland cancer	8.22e-07	4.2e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—salivary gland cancer	8.17e-07	4.18e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—salivary gland cancer	8.1e-07	4.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—salivary gland cancer	8.01e-07	4.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—salivary gland cancer	7.99e-07	4.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—salivary gland cancer	7.93e-07	4.06e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—salivary gland cancer	7.92e-07	4.05e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—salivary gland cancer	7.88e-07	4.03e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—salivary gland cancer	7.74e-07	3.96e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—salivary gland cancer	7.72e-07	3.95e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—salivary gland cancer	7.7e-07	3.94e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—salivary gland cancer	7.65e-07	3.91e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—salivary gland cancer	7.63e-07	3.9e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—salivary gland cancer	7.57e-07	3.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—salivary gland cancer	7.4e-07	3.78e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—salivary gland cancer	7.39e-07	3.78e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—salivary gland cancer	7.29e-07	3.73e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—salivary gland cancer	7.29e-07	3.73e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—salivary gland cancer	7.13e-07	3.64e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—salivary gland cancer	7.01e-07	3.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—salivary gland cancer	6.89e-07	3.52e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—salivary gland cancer	6.83e-07	3.49e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—salivary gland cancer	6.82e-07	3.49e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—salivary gland cancer	6.77e-07	3.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—salivary gland cancer	6.72e-07	3.44e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CREBBP—salivary gland cancer	6.71e-07	3.43e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—salivary gland cancer	6.66e-07	3.41e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—salivary gland cancer	6.58e-07	3.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—salivary gland cancer	6.5e-07	3.33e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—salivary gland cancer	6.48e-07	3.31e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—salivary gland cancer	6.46e-07	3.3e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—salivary gland cancer	6.44e-07	3.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—salivary gland cancer	6.37e-07	3.26e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—salivary gland cancer	6.37e-07	3.26e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—salivary gland cancer	6.31e-07	3.23e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—salivary gland cancer	6.27e-07	3.21e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—salivary gland cancer	6.23e-07	3.19e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—salivary gland cancer	6.22e-07	3.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—salivary gland cancer	6.09e-07	3.11e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—salivary gland cancer	5.99e-07	3.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—salivary gland cancer	5.96e-07	3.05e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—salivary gland cancer	5.6e-07	2.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—salivary gland cancer	5.42e-07	2.77e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—salivary gland cancer	5.39e-07	2.76e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—salivary gland cancer	5.22e-07	2.67e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—salivary gland cancer	5.18e-07	2.65e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—salivary gland cancer	4.99e-07	2.55e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—salivary gland cancer	4.79e-07	2.45e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—salivary gland cancer	4.78e-07	2.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—salivary gland cancer	4.62e-07	2.36e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—salivary gland cancer	4.57e-07	2.34e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—salivary gland cancer	4.42e-07	2.26e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	4.13e-07	2.11e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	3.38e-07	1.73e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—salivary gland cancer	2.95e-07	1.51e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—salivary gland cancer	2.81e-07	1.44e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	2.08e-07	1.06e-06	CbGpPWpGaD
